Adrenoleukodystrophy: Mechanisms and Clinical Care

Adrenoleukodystrophy represents one of the most clinically heterogeneous and devastating inborn errors of metabolism known to modern neurogenetics. Characterized by the progressive breakdown of myelin sheaths within the central nervous system and primary adrenocortical insufficiency, this condition exemplifies the complex intersection between cellular lipid trafficking and neuroinflammatory neurodegeneration. Understanding its underlying biochemistry, phenotypic spectrum, and evolving therapeutic landscape is critical for early diagnosis, life-saving intervention, and holistic patient management.

Adrenoleukodystrophy

1. Concise Definition

Adrenoleukodystrophy (ALD), specifically X-linked adrenoleukodystrophy (X-ALD), is a rare, monogenic metabolic disorder characterized by the systemic accumulation of saturated very long-chain fatty acids (VLCFAs) in biological tissues and physiological fluids. The metabolic defect arises from pathogenic mutations in the ABCD1 gene, which encodes the peroxisomal membrane transport protein adrenoleukodystrophy protein (ALDP). This loss of functional ALDP impedes the normal beta-oxidation of VLCFAs within peroxisomes, yielding toxic intracellular lipid concentrations.

Pathologically, this enzymatic blockade exerts its most profound and destructive consequences upon two principal organ systems: the central and peripheral nervous systems, and the endocrine adrenal cortex. Within the nervous system, the pathological accretion of unbranched VLCFAs—particularly hexacosanoic acid (C26:0) and tetracosanoic acid (C24:0)—triggers rapid, inflammatory demyelination in the cerebral hemispheres or an insidious, non-inflammatory distal axonopathy in the spinal cord. Concurrently, the accumulation of toxic lipid species in the adrenocortical cells initiates progressive primary adrenocortical insufficiency, rendering patients vulnerable to life-threatening adrenal crises.

2. Etymology & Linguistic Origin

The term adrenoleukodystrophy is a modern medical neologism derived from classical Greek and Latin morphemes that systematically delineate the anatomical and histological hallmarks of the disease:

• Adreno-: Originating from the Latin ad (“near” or “at”) and renes (“kidneys”), referring specifically to the adrenal (suprarenal) glands that undergo progressive atrophy and endocrine dysfunction.
• Leuko-: Originating from the Ancient Greek leukos (λευκός), signifying “white,” which in neuroanatomy denotes the myelinated white matter of the cerebrum, brainstem, and spinal cord.
• Dystrophy: Compounded from the Greek prefix dys- (δυσ-, indicating “abnormal,” “faulty,” or “difficult”) and the root trophe (τροφή, meaning “nourishment” or “development”), designating a pathological state marked by defective tissue nutrition, structural degradation, and degeneration.

The synthesized term was formally introduced into biomedical nomenclature in 1970 by the pediatric neuropathologists Michael Blaw and colleagues to replace ambiguous, non-specific descriptors such as “Schilder’s disease with bronzing” or “melanodermic leukodystrophy,” thereby providing a precise clinicopathological designation reflecting both endocrine and neurodegenerative involvement.

3. Pronunciation & Grammatical Form

• Pronunciation: The standard International Phonetic Alphabet (IPA) transcription is /əˌdriː.noʊˌluː.koʊˈdɪs.trə.fi/ (American English) or /əˌdriː.nəʊˌljuː.kəʊˈdɪs.trə.fi/ (British English).
• Grammatical Form: Compound noun (uncountable).
• Adjectival Forms: Adrenoleukodystrophic (e.g., “adrenoleukodystrophic phenotypes”); rarely, adrenoleukomyeloneuropathic when denoting spinal cord-predominant manifestations.
• Abbreviations: ALD, X-ALD (to emphasize the X-linked inheritance pattern).

4. Detailed Conceptual Explanation

To grasp the biological breadth of adrenoleukodystrophy, one must examine the peroxisome, an organelle essential for lipid anabolism and catabolism. Peroxisomes house the enzymatic machinery required for the beta-oxidation of straight-chain, saturated fatty acids possessing acyl chains of 22 or more carbons. Unlike long-chain fatty acids, which undergo oxidation within mitochondrial matrices, VLCFAs cannot passively diffuse across mitochondrial membranes and depend entirely on peroxisomal pathways for chain shortening. Translocation of cytosolic VLCFA-coenzyme A (CoA) esters into the peroxisomal lumen requires the membrane-bound ATP-binding cassette (ABC) transporter encoded by the ABCD1 locus.

When pathogenic variants disrupt ALDP integrity, the peroxisomal import of cytosolic VLCFA-CoA is severely diminished or abolished. Consequently, un-oxidized VLCFAs are shunted into cellular lipid synthesis pathways, resulting in excessive esterification into complex structural lipids, including cholesterol esters, phospholipids, and gangliosides. This lipid surplus disrupts cellular membrane dynamics, impairs membrane fluidity, downregulates sodium-potassium ATPase activity, and triggers severe endoplasmic reticulum stress. Furthermore, these foreign lipid aggregates trigger free-radical release, mitochondrial dysfunction, and lipid peroxidation, culminating in cellular apoptosis.

A critical hallmark of ALD is its phenotypic variability. The same inherited ABCD1 genetic mutation can manifest as catastrophic cerebral inflammatory demyelination in an eight-year-old child, as slow-progressing spastic paraparesis in a fifty-year-old adult, or as isolated adrenal failure in an infant. This profound discordance indicates that the primary biochemical lesion—the accumulation of VLCFAs—is an absolute metabolic prerequisite for disease manifestation, yet it is insufficient to dictate the specific phenotypic outcome. Secondary epigenetic modifiers, environmental triggers (such as cranial trauma or viral exposure), and polygenic inflammatory susceptibility loci modulate whether an individual develops localized autoimmune-like cerebral destruction or chronic axonopathy.

Furthermore, while ALD is inherited in an X-linked recessive pattern, heterozygous females are not merely silent genetic carriers. Due to non-random X-chromosome inactivation, metabolic exhaustion over time, and subtle systemic lipid toxicity, up to 80% of heterozygous women eventually manifest sensory-motor symptoms akin to a mild myelopathy by their sixth decade of life, demonstrating that ALD acts as an X-linked dominant condition with variable, age-dependent penetrance in females.

5. Historical Development

The clinical and scientific recognition of adrenoleukodystrophy evolved through several decisive milestones over the twentieth century:

• 1923 (Initial Clinical Observation): German physicians Ernst Siemerling and Hans Gerhard Creutzfeldt documented a landmark case of a young boy who presented with hyperpigmented skin (reminiscent of Addison’s disease) accompanied by rapidly progressive neurological deterioration and cerebral white matter degeneration. This condition was temporarily classified within the broad, heterogeneous umbrella of “diffuse cerebral sclerosis.”
• 1970 (Nomenclature and Entity Definition): Michael Blaw, in collaborative studies evaluating familial associations between cerebral white matter loss and hypocortisolemia, recognized the disorder as a distinct clinical entity and coined the term adrenoleukodystrophy.
• 1976–1981 (Biochemical Discovery): Research groups led by Hugo W. Moser and Ann B. Moser identified that tissues, cultured skin fibroblasts, and plasma from ALD patients exhibited profound elevations of unbranched VLCFAs, definitively demonstrating that the disorder constitutes a peroxisomal metabolic storage defect rather than a primary autoimmune encephalopathy.
• 1989 (Therapeutic Exploration via Lorenzo’s Oil): Augusto and Michaela Odone pioneered “Lorenzo’s Oil” (a 4:1 mixture of glyceryl trioleate and glyceryl trierucate) to competitively inhibit the microsomal elongation of endogenous saturated fatty acids. While clinical trials demonstrated normalization of plasma VLCFA levels, subsequent studies clarified that the mixture does not arrest cerebral demyelination once active inflammatory neurodegeneration has begun.
• 1993 (Molecular Cloning): Patrick Aubourg and colleagues identified and cloned the ABCD1 gene on the X chromosome (Xq28), elucidating its sequence, confirming its membership in the ATP-binding cassette transporter superfamily, and establishing the molecular framework for genetic diagnostics and contemporary gene therapy.

6. Theoretical Foundations & Pathophysiological Frameworks

The pathophysiology of ALD is best understood through a three-stage model: primary biochemical failure, microvascular/microglial activation, and secondary immune-mediated neuroinflammation.

The first tier involves metabolic disruption. Elevated VLCFA-CoA molecules incorporate into the lipid bilayers of oligodendrocytes, microglial membranes, and steroidogenic cells of the adrenal zona fasciculata. In the adrenal glands, abnormal cholesterol-VLCFA esters cannot be cleaved by hormone-sensitive lipase into free cholesterol, impeding the rate-limiting step in steroidogenesis. Over time, physical disruption of adrenocortical mitochondrial membranes by VLCFA accumulation causes cellular necrosis and adrenal atrophy.

The second tier involves oxidative stress and bioenergetic compromise. Within the central nervous system, excessive cytosolic VLCFAs provoke the dysregulated opening of mitochondrial permeability transition pores, triggering electron transport chain failure. Intracellular reactive oxygen species (ROS) escalate, oxidatively degrading neighboring lipids, structural proteins, and neurofilaments. In oligodendrocytes, this bioenergetic failure alters myelin sheath integrity, leading to myelin uncoupling and early neuroaxonal dysfunction.

The third tier explains the sudden, explosive transition into the cerebral inflammatory phenotype. When structurally altered myelin fragments enter the perivascular spaces, resident microglia identify these anomalous lipid-protein aggregates as damage-associated molecular patterns (DAMPs). Microglial activation initiates a massive release of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ). This cytokine storm compromises the blood-brain barrier, allowing peripheral CD8+ cytotoxic T cells and CD4+ helper T cells to infiltrate the brain parenchyma, driving rapid demyelination resembling an aggressive, non-remitting autoimmune attack.

7. Key Components, Types & Dimensions

According to comprehensive clinical classifications, such as those cataloged in GeneReviews for X-ALD, adrenoleukodystrophy presents along a broad spectrum of distinct clinical phenotypes:

• Childhood Cerebral ALD (CCALD): The most devastating and aggressive phenotype, typically manifesting between ages 3 and 10. Characterized by behavioral changes, cognitive regression, auditory and visual deficits, gait disturbances, seizures, and progression to a vegetative state or death within 2 to 4 years of clinical onset if untreated.
• Adrenomyeloneuropathy (AMN): The most common manifestation, typically emerging in men in their late 20s to 40s. AMN is a slowly progressive, non-inflammatory distal axonopathy affecting the spinal cord corticospinal tracts and dorsal columns, causing spastic paraparesis, sensory ataxia, sphincter dysfunction, and erectile impotence. Approximately 20% of AMN patients subsequently develop cerebral demyelination.
• Adolescent and Adult Cerebral ALD: Clinically equivalent to CCALD in its rapid inflammatory demyelination and fatal course, but with onset spanning adolescence or adulthood, often initially misdiagnosed as psychiatric illness or multiple sclerosis.
• Addison-Only ALD: Manifests as primary adrenal insufficiency without overt neurological impairment, presenting in boys or adult men with fatigue, skin hyperpigmentation, hypoglycemia, and vulnerability to life-threatening adrenal crisis. Many eventually develop AMN later in life.
• Symptomatic Heterozygous Females: Carrier women who develop adult-onset neurological symptoms, typically presenting in their fourth to sixth decades with mild-to-moderate spastic paraparesis, paresthesias, urinary urgency, and gait instability, rarely involving cerebral disease or adrenal insufficiency.
• Asymptomatic / Pre-symptomatic Carriers: Individuals harboring pathogenic ABCD1 variants identified through family pedigree screening or universal newborn screening, demonstrating elevated VLCFAs without overt neurological or endocrine manifestations.

8. Examples & Illustrative Cases

Case Illustration 1: Childhood Cerebral Demyelination
An 8-year-old boy with normal developmental milestones begins displaying attention deficits, declining academic performance, and emotional outbursts at school. Initial evaluations suggest attention-deficit/hyperactivity disorder (ADHD). Six months later, he experiences progressive visual impairment and subtle gait clumsiness. A magnetic resonance imaging (MRI) scan of the brain reveals symmetric T2-weighted and FLAIR hyperintensities throughout the corpus callosum and parieto-occipital white matter, surrounded by a distinct peripheral rim of contrast enhancement indicating blood-brain barrier disruption. Plasma biochemical screening confirms elevated hexacosanoic acid (C26:0) and an elevated C26:0/C22:0 ratio, diagnostic of childhood cerebral ALD. Endocrine panels show elevated adrenocorticotropic hormone (ACTH) with reduced cortisol, confirming occult adrenal insufficiency. Because the disease was detected at an advanced neuroinflammatory stage (Loes MRI score > 10), the therapeutic window for curative cellular therapy has closed, requiring palliative support.

Case Illustration 2: Adrenomyeloneuropathy in Adulthood
A 34-year-old man presents to an outpatient neurology clinic with a five-year history of progressive leg stiffness, unsteadiness when walking in the dark, and chronic urinary urgency. A physical examination demonstrates lower-extremity hyperreflexia, bilateral extensor plantar responses (Babinski sign), and reduced vibratory sensation up to the anterior superior iliac spines. Brain MRI shows no white matter demyelination, but spinal MRI reveals moderate thoracic cord atrophy. Review of medical history uncovers that he was diagnosed with Addison’s disease at age 12 and maintained on hydrocortisone and fludrocortisone. Genetic sequencing reveals a hemizygous pathogenic variant in ABCD1, confirming a diagnosis of adrenomyeloneuropathy. Management focuses on symptomatic tone control, physical therapy, and periodic brain MRI surveillance to detect secondary cerebral demyelination early.

9. Measurement & Assessment

Accurate clinical assessment of adrenoleukodystrophy relies on a synthesis of biochemical testing, neuroimaging, molecular diagnostics, and endocrine evaluations:

• Biochemical Analysis (Plasma VLCFAs): The historical cornerstone of diagnosis. High-performance liquid chromatography or tandem mass spectrometry (LC-MS/MS) quantifies C26:0, the ratio of C26:0 to docosanoic acid (C26:0/C22:0), and the ratio of tetracosanoic acid to docosanoic acid (C24:0/C22:0). Elevated values confirm the metabolic defect in over 99% of hemizygous males, though up to 15% of heterozygous females may present with borderline or normal levels.
• Molecular Genetic Testing: Direct Sanger sequencing or next-generation sequencing of the ABCD1 gene detects point mutations, frameshifts, or large deletions. It serves as the gold standard for definitive diagnosis, female carrier validation, and prenatal diagnosis.
• Neuroimaging (The Loes Severity Score): Magnetic resonance imaging (MRI) is essential for monitoring cerebral disease. The Loes scoring system is a 34-point quantitative metric that systematically evaluates the extent and topography of white matter demyelination and cerebral atrophy. A Loes score of 0 denotes normal brain parenchyma, while a score of 0.5 to 9 represents early-stage, salvageable cerebral involvement where cellular intervention is viable. Post-gadolinium T1-weighted sequences are evaluated for peripheral rim enhancement, an indicator of active inflammatory breakdown of the blood-brain barrier.
• Endocrine Assessment: Measurement of early morning plasma ACTH, baseline serum cortisol, and dynamic ACTH stimulation tests (cosyntropin testing). Markedly elevated baseline ACTH levels, even with low-normal cortisol, indicate subclinical adrenocortical failure.
• Newborn Screening (NBS): Universal newborn screening using flow-injection tandem mass spectrometry quantifies 1-hexacosanoyl-2-lyso-sn-glycero-3-phosphocholine (C26:0-lyso-PC) in dried blood spots, enabling identification of affected neonates well before neurological or endocrine symptom onset.

10. Applications & Practical Significance

The practical management of ALD has been transformed by universal newborn screening and early interventions. Diagnosing an infant at birth removes the diagnostic odyssey and allows clinical teams to construct a lifelong surveillance roadmap:

Surveillance protocols mandate serial brain MRIs (every 6 months between ages 3 and 12, then annually) alongside longitudinal endocrine monitoring. Detecting asymptomatic adrenal failure allows for timely glucocorticoid and mineralocorticoid replacement therapy, preventing life-threatening adrenal crises.

Critically, when neuroimaging identifies the earliest emergence of cerebral demyelination (Loes score between 0.5 and 9 with gadolinium enhancement) prior to major clinical deficits, timely intervention with allogeneic hematopoietic stem cell transplantation (HSCT) or autologous ex vivo lentiviral gene therapy (elivaldogene autotemcel) can arrest inflammatory demyelination. Donor-derived microglial-like cells migrate into the central nervous system, halt the neuroinflammatory cascade, and preserve neurocognitive function. Conversely, identifying patients with the non-inflammatory AMN phenotype redirects clinical focus toward physical rehabilitation, management of spasticity with antispasmodics or intrathecal baclofen, and targeted urological interventions for neurogenic bladder dysfunction.

11. Research & Empirical Evidence

Seminal investigations have continuously advanced our understanding of ALD biology and treatment:

In 1990, William Krivit, Patrick Aubourg, and colleagues established the efficacy of allogeneic HSCT in arresting cerebral ALD when performed during early stages of the disease. Long-term outcome data gathered over three decades have shown that donor microglial chimerism successfully terminates the neuroinflammatory cycle, whereas transplanting patients with advanced demyelination (Loes score > 9) is ineffective and associated with high mortality.

Florian Eichler, David A. Williams, and colleagues conducted clinical trials using autologous hematopoietic stem cells transduced with a lentiviral vector encoding normal human ABCD1 cDNA (elivaldogene autotemcel). The findings, published in The New England Journal of Medicine, showed that ex vivo gene addition achieved stabilization of cerebral demyelination with overall survival rates comparable to allogeneic transplant, without the risks of graft-versus-host disease (GVHD) or human leukocyte antigen (HLA) donor incompatibility. This work led to the formal regulatory approval of elivaldogene autotemcel in several jurisdictions.

In the biochemical domain, Hugo W. Moser led extensive multinational prospective trials on Lorenzo’s Oil. While confirming that Lorenzo’s Oil lowers plasma VLCFA concentrations, Moser et al. (2005) demonstrated that it failed to reverse or halt existing cerebral inflammatory demyelination. However, prophylactic use in neurologically asymptomatic boys showed potential benefit in reducing the likelihood of subsequent cerebral involvement, sparking ongoing debate regarding its precise role in clinical management.

12. Cultural & Cross-Cultural Considerations

Adrenoleukodystrophy exhibits no geographic, racial, or ethnic predilection, maintaining a stable international incidence of approximately 1 in 15,000 to 1 in 20,000 live births across all populations. However, healthcare disparities significantly influence outcomes across different regions:

In nations with widespread newborn screening panels (such as multiple U.S. states and progressive European public health jurisdictions), affected infants are identified early and placed into structured surveillance pipelines. In contrast, in regions without newborn screening, ALD diagnoses are typically made only after marked, irreversible neurocognitive decline has occurred, leaving these patients ineligible for cell therapy.

Furthermore, access to advanced therapeutics—such as HLA-matched stem cell transplantation, intensive care monitoring, and novel gene therapies carrying multimillion-dollar costs—highlights major socioeconomic inequities in rare disease care. Cultural perceptions surrounding genetic counseling, prenatal diagnosis, and termination of affected pregnancies also vary across communities, underscoring the need for culturally competent genetic counseling tailored to each family’s values.

13. Criticisms, Debates & Limitations

Despite major scientific advancements, several controversies persist within the ALD field:

• The Genotype-Phenotype Disconnect: A primary puzzle is the complete lack of correlation between specific ABCD1 mutations and the resulting clinical phenotype. Brothers or monozygotic twins harboring identical genetic mutations can manifest completely divergent disease trajectories—one developing fatal childhood cerebral demyelination while the other remains an asymptomatic or mildly affected adult with AMN. The search for secondary “modifier genes” has identified candidate loci (e.g., related to oxidative defense, microglial activation, and cholesterol homeostasis), but universal predictive biomarkers remain elusive.
• Transplantation Risks vs. Gene Therapy: Although allogeneic HSCT has saved many lives, it carries substantial risks, including graft failure, conditioning regimen toxicity, and graft-versus-host disease. While autologous lentiviral gene therapy circumvents GVHD and donor matching, concerns remain regarding the long-term potential for insertional oncogenesis, which requires years of vigilant hematologic surveillance.
• Lorenzo’s Oil Efficacy: The clinical utility of Lorenzo’s Oil remains debated. While popularized in mass culture through the 1992 film Lorenzo’s Oil, major clinical trials demonstrated its inability to alter the course of active cerebral demyelination, illustrating the divide between normalizing a surrogate blood biomarker and altering complex neuropathology.
• Surveillance Protocols for Carrier Females: Historically dismissed as unaffected carriers, the broad prevalence of myelopathy in adult women with ABCD1 mutations was long overlooked by the medical community, resulting in diagnostic delays and fragmented symptomatic care for female patients.

14. Related Terms & Distinctions

To prevent diagnostic misclassification, adrenoleukodystrophy must be distinguished from several related disorders:

• Zellweger Spectrum Disorders: Severe peroxisomal biogenesis disorders (caused by mutations in PEX genes) that disrupt all peroxisomal matrix protein import. Unlike ALD, which impairs the import of VLCFA-CoA alone, Zellweger spectrum disorders affect plasmalogen synthesis, phytanic acid oxidation, and bile acid biosynthesis, presenting neonatally with craniofacial dysmorphisms, hepatic dysfunction, and profound hypotonia.
• Metachromatic Leukodystrophy (MLD): A lysosomal storage disease resulting from arylsulfatase A deficiency, which leads to sulfatide accumulation. While MLD causes progressive cerebral demyelination and peripheral neuropathy, it does not involve the adrenal cortex, and plasma VLCFA profiles remain normal.
• Multiple Sclerosis (MS): An acquired autoimmune inflammatory demyelinating disease of the central nervous system. Adult cerebral ALD and AMN are frequently misdiagnosed as primary progressive or relapsing-remitting MS. However, MS does not cause adrenal insufficiency or elevated VLCFAs, and ALD white matter lesions typically demonstrate a confluent, posterior-predominant distribution pattern distinct from the multifocal periventricular distribution of MS plaques.
• Primary Adrenal Insufficiency (Addison’s Disease): An endocrine disorder commonly caused by autoimmune destruction of the adrenal cortex (marked by 21-hydroxylase autoantibodies). ALD represents the underlying etiology in approximately one-third of young boys presenting with idiopathic Addison’s disease; this distinction must be evaluated using plasma VLCFA panels.

15. Summary & Key Takeaways

Adrenoleukodystrophy is an X-linked metabolic leukodystrophy caused by pathogenic mutations in the ABCD1 gene, preventing normal peroxisomal beta-oxidation and leading to the systemic accumulation of saturated very long-chain fatty acids. This metabolic disruption leads to two primary consequences: adrenal failure and neurological damage, the latter manifesting as either rapidly destructive cerebral demyelination or chronic progressive adrenomyeloneuropathy. Management relies on early identification through newborn screening and structured MRI surveillance, as allogeneic stem cell transplantation and gene therapy can halt cerebral neuroinflammation only when administered in early-stage disease. A multidisciplinary approach uniting pediatric and adult neurologists, endocrinologists, genetic counselors, and rehabilitation specialists is essential to optimize clinical outcomes across the lifespan.

Ultimately, adrenoleukodystrophy highlights the vital connection between cellular biochemistry and clinical medicine. From identifying a peroxisomal transporter defect to developing targeted gene therapies, ongoing research into ALD continues to expand our understanding of inborn errors of metabolism and drive progress in neurotherapeutics.

References

• Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W., Raymond, G. V., Sankar, R., Shah, A. J., Sevin, C., Semilly, O. P., Gupta, A. O., Asang, E., Lee, S., Aubourg, P., & Williams, D. A. (2017). Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. The New England Journal of Medicine, 377(17), 1630–1638. https://doi.org/10.1056/NEJMoa1700518
• Engelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. T. (2012). X-linked adrenoleukodystrophy (X-ALD): Clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet Journal of Rare Diseases, 7, Article 51. https://doi.org/10.1186/1750-1172-7-51
• Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016). Adrenoleukodystrophy – neuroendocrine pathogenesis and re-defining the clinical spectrum. Nature Reviews Endocrinology, 12(10), 606–615. https://doi.org/10.1038/nrendo.2016.90
• Loes, D. J., Hite, S., Moser, H., Stillman, A. E., Shapiro, E., Neetens, I., Rosas, R. R., & Latchaw, R. E. (1994). Adrenoleukodystrophy: A scoring method for brain MR observations. American Journal of Neuroradiology, 15(9), 1761–1766.
• Moser, H. W., Raymond, G. V., Lu, S. E., Muenz, L. R., Moser, A. B., Xu, J., Vaishnav, P., Cox, C. S., & Zhu, J. (2005). Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Archives of Neurology, 62(7), 1073–1080. https://doi.org/10.1001/archneur.62.7.1073